The PIPE included common stock and pre-funded warrants

Davis Polk advised the joint placement agents in connection with Maze Therapeutics, Inc.’s $150 million private placement of common stock and pre-funded warrants.

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases.

The Davis Polk corporate team included partner Emily Roberts and associate Paula Gergen. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post